Alport syndrome: new advances in the last decade
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Alport syndrome (AS) is a progressive hereditary nephritis that is often accompanied by sensorineural hearing loss and ocular abnormalities. It is inherited in three modes of X-linked (XLAS), autosomal recessive (ARAS), and autosomal dominant (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ARAS and ADAS are caused by those in COL4A3 or COL4A4. There is currently no curative treatment for AS; however, angiotensin-converting enzyme inhibitors (ACEi) can improve the outcome of AS. In the past decade, multiple studies have shown that early intervention with ACEi upon isolated microscopic hematuria or microalbuminuria could delay disease progression, and early diagnosis is crucial for early treatment. Therefore, a new classification of AS based on molecular diagnoses has been proposed, including the paradigm shift of re-classifying female “carriers” to “patients” and “thin basement membrane nephropathy” to “ADAS.” In addition, with the detection of COL4A mutations in some patients with biopsy-confirmed IgA nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease of unknown origin, it is suggested that the phenotype of AS should be expanded. In this review, we highlight the landmark studies and guidelines published over the past decade and introduce strategies for early diagnosis and treatment to improve the outcomes of AS.
Abstract
Alport syndrome (AS) is a progressive hereditary nephritis that is often accompanied by sensorineural hearing loss and ocular abnormalities. It is inherited in three modes of X-linked (XLAS), autosomal recessive (ARAS), and autosomal dominant (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ARAS and ADAS are caused by those in COL4A3 or COL4A4. There is currently no curative treatment for AS; however, angiotensin-converting enzyme inhibitors (ACEi) can improve the outcome of AS. In the past decade, multiple studies have shown that early intervention with ACEi upon isolated microscopic hematuria or microalbuminuria could delay disease progression, and early diagnosis is crucial for early treatment. Therefore, a new classification of AS based on molecular diagnoses has been proposed, including the paradigm shift of re-classifying female “carriers” to “patients” and “thin basement membrane nephropathy” to “ADAS.” In addition, with the detection of COL4A mutations in some patients with biopsy-confirmed IgA nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease of unknown origin, it is suggested that the phenotype of AS should be expanded. In this review, we highlight the landmark studies and guidelines published over the past decade and introduce strategies for early diagnosis and treatment to improve the outcomes of AS.
참고문헌 (57)
- Nozu Kandai, "Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome", Kidney Research and Clinical Practice, 39(4), pp.402~413 (2020), 대한신장학회[DOI]
- Kashtan CE, "Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020", Pediatr Nephrol, 36, pp.711~719 (2021)
- Savige J, "Expert consensus guidelines for the genetic diagnosis of Alport syndrome", Pediatr Nephrol, 34, pp.1175~1189 (2019)
- Levey AS, "Nomenclature for kidney function and disease : report of a Kidney Disease : Improving Global Outcomes(KDIGO)consensus conference", Kidney Int, 97, pp.1117~1129 (2020)
- Nozu K, "A review of clinical characteristics and genetic backgrounds in Alport syndrome", Clin Exp Nephrol, 23, pp.158~168 (2019)
- Boutaud A, "Type IV collagen of the glomerular basement membrane : evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains", J Biol Chem, 275, pp.30716~30724 (2000)
- Bekheirnia MR, "Genotype-phenotype correlation in X-linked Alport syndrome", J Am Soc Nephrol, 21, pp.876~883 (2010)
- Jais JP, "X-linked Alport syndrome : natural history in 195 families and genotype-phenotype correlations in males", J Am Soc Nephrol, 11, pp.649~657 (2000)
- Gross O, "Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome : impact on clinical counselling", Nephrol Dial Transplant, 17, pp.1218~1227 (2002)
- Jais JP, "X-linked Alport syndrome : natural history and genotype-phenotype correlations in girls and women belonging to 195 families : a"European Community Alport Syndrome Concerted Action"study", J Am Soc Nephrol, 14, pp.2603~2610 (2003)
- Yamamura T, "Natural history and genotype-phenotype correlation in female X-linked Alport syndrome", Kidney Int Rep, 2, pp.850~855 (2017)
- Lee JM, "Features of autosomal recessive Alport syndrome : a systematic review", J Clin Med, 8, pp.178~ (2019)
- Oka M, "Natural history of genetically proven autosomal recessive Alport syndrome", Pediatr Nephrol, 29, pp.1535~1544 (2014)
- Kamiyoshi N, "Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome", Clin J Am Soc Nephrol, 11, pp.1441~1449 (2016)
- Kashtan CE, "Alport syndrome: an inherited disorder of renal, ocular, and cochlear basement membranes", Medicine(Baltimore), 78, pp.338~360 (1999)
- "Alport’s syndrome: Orphanet encyclopedia" (2001)[URL]
- Savige J, "Ocular features in Alport syndrome : pathogenesis and clinical significance", Clin J Am Soc Nephrol, 10, pp.703~709 (2015)
- Adam J, "Genetic testing can resolve diagnostic confusion in Alport syndrome", Clin Kidney J, 7, pp.197~200 (2014)
- Yao XD, "Challenge in pathologic diagnosis of Alport syndrome : evidence from correction of previous misdiagnosis", Orphanet J Rare Dis, 7, pp.100~ (2012)
- Warady BA, "Alport syndrome classification and management", Kidney Med, 2, pp.639~649 (2020)
- Heidet L, "The renal lesions of Alport syndrome", J Am Soc Nephrol, 20, pp.1210~1215 (2009)
- Hashimura Y, "Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain", Kidney Int, 85, pp.1208~1213 (2014)
- Nakanishi K, "Immunohistochemical study of alpha 1-5 chains of type IV collagen in hereditary nephritis", Kidney Int, 46, pp.1413~1421 (1994)
- 정경환, "IgA nephropathy combined with thin basement membrane nephropathy in children", Kidney Research and Clinical Practice, 32(4), pp.194~195 (2013), 대한신장학회
- Lennon R, "Could this be Alport syndrome?", Clin J Am Soc Nephrol, 16, pp.1743~1745 (2021)
- Savige J, "Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome : refining the ACMG criteria", Eur J Hum Genet, 29, pp.1186~1197 (2021)
- Yamamura T, "Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome", Kidney Int, 98, pp.1605~1614 (2020)
- Gross O, "Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome", Kidney Int, 63, pp.438~446 (2003)
- Gross O, "Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy", Kidney Int, 81, pp.494~501 (2012)
- Gross O, "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome", Kidney Int, 97, pp.1275~1286 (2020)
- Groopman EE, "Diagnostic utility of exome sequencing for kidney disease", N Engl J Med, 380, pp.142~151 (2019)
- Gast C, "Collagen(COL4A)mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis", Nephrol Dial Transplant, 31, pp.961~970 (2016)
- Kashtan CE, "Alport syndrome: a unified classification of genetic disorders of collagen IV α345. A position paper of the Alport Syndrome Classification Working Group", Kidney Int, 93, pp.1045~1051 (2018)
- Grunfeld JP, "Renal prognosis in women with hereditary nephritis", Clin Nephrol, 23, pp.267~271 (1985)
- Rana K, "Persistent familial hematuria in children and the locus for thin basement membrane nephropathy", Pediatr Nephrol, 20, pp.1729~1737 (2005)
- Imafuku A, "How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists", Clin Exp Nephrol, 24, pp.651~656 (2020)
- Yamamura T, "Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome", Mol Genet Genomic Med, 7, pp.e883~ (2019)
- Kashtan CE, "Clinical practice recommendations for the treatment of Alport syndrome : a statement of the Alport Syndrome Research Collaborative", Pediatr Nephrol, 28, pp.5~11 (2013)
- ESCAPE Trial Group, "Strict blood-pressure control and progression of renal failure in children", N Engl J Med, 361, pp.1639~1650 (2009)
- Nakanishi K, "Efficacy and safety of lisinopril for mild childhood IgA nephropathy : a pilot study", Pediatr Nephrol, 24, pp.845~849 (2009)
- Gipson DS, "Clinical trial of focal segmental glomerulosclerosis in children and young adults", Kidney Int, 80, pp.868~878 (2011)
- Gross O, "Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis", Nephrol Dial Transplant, 19, pp.1716~1723 (2004)
- Webb NJ, "Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome", Pediatr Nephrol, 28, pp.737~743 (2013)
- van den Belt SM, "Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD", J Am Soc Nephrol, 29, pp.2225~2233 (2018)
- Kaito H, "The effect of aldosterone blockade in patients with Alport syndrome", Pediatr Nephrol, 21, pp.1824~1829 (2006)
- Faul C, "The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A", Nat Med, 14, pp.931~938 (2008)
- Naesens M, "Calcineurin inhibitor nephrotoxicity", Clin J Am Soc Nephrol, 4, pp.481~508 (2009)
- Callis L, "Long-term effects of cyclosporine A in Alport’s syndrome", Kidney Int, 55, pp.1051~1056 (1999)
- Callis L, "Effect of cyclosporin A on proteinuria in patients with Alport’s syndrome", Pediatr Nephrol, 6, pp.140~144 (1992)
- Charbit M, "Cyclosporin therapy in patients with Alport syndrome", Pediatr Nephrol, 22, pp.57~63 (2007)
- Massella L, "Cyclosporine A treatment in patients with Alport syndrome : a single-center experience", Pediatr Nephrol, 25, pp.1269~1275 (2010)
- 김지현, "Renal Syndromic Hearing Loss is Common in Childhood-onset Chronic Kidney Disease", Journal of Korean Medical Science, 35(44), pp.1~11 (2020), 대한의학회[DOI]
- Alves FR, "Revision about hearing loss in the Alport’s syndrome, analyzing the clinical, genetic and bio-molecular aspects", Braz J Otorhinolaryngol, 71, pp.813~819 (2005)
- Zhang X, "X-linked Alport syndrome : pathogenic variant features and further auditory genotype-phenotype correlations in males", Orphanet J Rare Dis, 13, pp.229~ (2018)
- "Reata announces positive results from year 2 of the pivotal phase 3 CARDINAL study of bardoxolone methyl in patients with Alport syndrome" (2020)[URL]
- de Zeeuw D, "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease", N Engl J Med, 369, pp.2492~2503 (2013)
- Gomez IG, "Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways", J Clin Invest, 125, pp.141~156 (2015)